A Study of Viracept in HIV-Positive Women

Completed · Phase 2

Conditions studied: HIV Infections

In brief

The purpose of this study is to see if it is safe and effective to give Viracept plus stavudine (d4T) plus lamivudine (3TC) to HIV-positive women with a CD4 count \<= 400 cells/mm3. This study also examines how the body handles Viracept when given with d4T and 3TC.

Key facts

Study ID

NCT00002171

Run by

Agouron Pharmaceuticals

Last updated by the study team

2005-06-24

Who can join

Age: 13 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Patients must have:
• HIV infection.
• CD4 T cell count <= 400 cells/mm3.

You may not qualify if…

• Prior Medication:
• Excluded:
• Prior therapy or less than 1 month of therapy with d4T and/or 3TC.
• Prior protease inhibitor therapy.

Where it is running

• Univ of Alabama at Birmingham — Birmingham, Alabama, United States
• Univ of Southern California / LA County USC Med Cntr — Los Angeles, California, United States
• HIV Outpatient Clinics / LA State Univ Med Ctr — New Orleans, Louisiana, United States
• Baylor Univ — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.